Authors : Esha S. Rithe; Dr. Sachin J. Dighade; Samiksha S. Bhamburkar; Reema R. Mangwani; Akshay S. Raut; Ashish L. Pohane

Volume/Issue : Volume 10 - 2025, Issue 3 - March

---

Google Scholar : https://tinyurl.com/28sfmnxy

Scribd : https://tinyurl.com/bdeavtfc

DOI : https://doi.org/10.38124/ijisrt/25mar420

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

---

Abstract : Pharmacogenomics and personalized medicine have revolutionized the landscape of drug therapy by optimizing treatment outcomes through the integration of genetic insights. This review explores the role of pharmacogenomics in optimizing drug therapy, discusses the advances in personalized medicine, particularly in oncology, & highlights the challenges and future potential of this approach. With a focus on Indian healthcare perspectives, this article underscores the importance of genetic testing, cost considerations, and the ethical dimensions of personalized medicine.

Keywords : Pharmacogenomics, Genetic Polymorphisms, Genetic Mutations.

References :

1. Pirmohamed M. Pharmacogenomics: Promise for personalizing medicine. Br J Clinically  Pharmacology . 2023;85(5):936-945.
2. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: From bench to byte. Clinically Pharmacology  Ther. 2023;102(5):781-783.
3. Indian Pharmacogenomics Database (IPD). Indian Journal of Pharmacology. 2022.
4. Dhanasekaran R, et al. Pharmacogenomics in Cancer Therapy: Opportunities and Challenges. Asian Pac J Cancer Prev. 2023;24(3):895-904.
5.  Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2:485–490.
6. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473–8.
7. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A. 2000;97:10613–8
8. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61. 
9. Salerno RA, Lesko LJ. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics. 2004;5:503–5.
10. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61.
11. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001;29:306–9.
12. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet. 2004;5:676–80.
13. Billings PR. Genetic nondiscrimination. Nat Genet. 2005;37:559–60.
14. Frueh FW, Goodsaid F, Rudman A, Huang SM, Lesko LJ. The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J. 2005;5:218–20
15. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200.